Patent ID: 8580743
Filing Date: 2013-11-12
Classification: A61K,A61P,C07K,Y02A

Abstract:
1. A pharmaceutical drug comprising: an effective amount of a protein, or a salt thereof, wherein the protein, or a salt thereof, comprises a mutant galectin 9 protein having β-galactoside binding activity and having the structure (N-CRD)-Linker-(C-CRD), wherein the N-CRD (N-terminal Carbohydrate Recognition Domain) is (a) a polypeptide having the amino acid sequence of SEQ ID NO: 3, (b) a variant thereof differing from the amino acid sequence of SEQ ID NO: 3 by a deletion, substitution or addition of 1 to 8 amino acid residues and maintaining a carbohydrate recognition activity of N-CRD of natural galectin 9, or (c) a variant thereof having an amino acid sequence at least 70% homologous to SEQ ID NO: 3 and maintaining a carbohydrate recognition activity of N-CRD of natural galectin 9; wherein the C-CRD (C-terminal Carbohydrate Recognition Domain) is (a) a polypeptide having the amino acid sequence of SEQ ID NO: 4, (b) a variant thereof differing from the amino acid sequence of SEQ ID: 4 by a deletion, substitution or addition of 1 to 21 amino acid residues and maintaining a carbohydrate recognition activity of C-CRD of natural galectin 9, or (c) a variant thereof having an amino acid sequence at least 70% homologous to SEQ ID NO: 4, and maintaining a carbohydrate recognition activity of C-CRD of natural galectin 9; and wherein the Linker is (a) an amino acid sequence consisting of 2 arbitrary natural amino acid residues, or (b) the amino acid sequence Arg Ile Pro, and wherein the pharmaceutical drug is an immunoregulator or immunomodulator capable of treating refractory autoimmune disease, pain disorder, asthmatic disease, rheumatism, rheumatoid arthritis, allergic disease, inflammatory disease, or a disorder related to bone metabolism.